Astria Therapeutics Inc. (ATXS) NASDAQ
$10.54 (0.01) (-0.10%)
Market Cap: $579.23M
As of 04/18/24 04:00 PM EDT. Market closed.
Astria Therapeutics Inc. (ATXS)
NASDAQ
$10.54
(0.01) (-0.10%)
Market Cap: $579.23M
As of 04/18/24 04:00 PM EDT. Market closed.
Add to Portfolio
COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
Address
.
PRICE CHART FOR ASTRIA THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$10.51
Previous Close
$10.55
Days Range
$10.43 - $10.87
52 week range
$4.26 - $16.80
Volume
319,177
Avg. Volume (30 days)
993,219
Market Cap
$579.23M
Dividend Yield
-
P/E
-
Shares Outstanding
54,903,061
Open
$10.51
Previous Close
$10.55
Days Range
$10.43 - $10.87
52 week range
$4.26 - $16.80
Volume
319,177
Avg. Volume (30 days)
993,219
Market Cap
$579.23M
Dividend Yield
-
P/E
-
Shares Outstanding
54,903,061
FINANCIAL STATEMENTS FOR ASTRIA THERAPEUTICS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ASTRIA THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Morabito Christopher | Chief Medical Officer | Apr 01, 2024 | Option Exercise | $3.87 | 10,000 | 38,700 | 10,000 | Apr 03, 2024, 04:05 PM |
| Morabito Christopher | Chief Medical Officer | Apr 01, 2024 | Sale | $13.59 | 10,000 | 135,939 | 0 | Apr 03, 2024, 04:05 PM |
| PERCEPTIVE ADVISORS LLC | Director | Feb 01, 2024 | Buy | $12.09 | 2,481,350 | 29,999,522 | 4,873,721 | Feb 05, 2024, 05:02 PM |
| Morabito Christopher | Chief Medical Officer | Jan 29, 2024 | Option Exercise | $3.87 | 9,200 | 35,604 | 9,200 | Jan 30, 2024, 05:03 PM |
| Morabito Christopher | Chief Medical Officer | Jan 26, 2024 | Option Exercise | $3.87 | 800 | 3,096 | 800 | Jan 30, 2024, 05:03 PM |
| Morabito Christopher | Chief Medical Officer | Jan 29, 2024 | Sale | $11.15 | 9,200 | 102,552 | 0 | Jan 30, 2024, 05:03 PM |
| Morabito Christopher | Chief Medical Officer | Jan 26, 2024 | Sale | $11.02 | 800 | 8,812 | 0 | Jan 30, 2024, 05:03 PM |
| PERCEPTIVE ADVISORS LLC | Director | Dec 21, 2023 | Buy | $6.20 | 740,000 | 4,588,000 | 2,392,371 | Dec 22, 2023, 02:51 PM |
| PERCEPTIVE ADVISORS LLC | Director | Oct 16, 2023 | Buy | $6.51 | 1,074,608 | 6,999,996 | 1,652,371 | Oct 18, 2023, 04:11 PM |
| PERCEPTIVE ADVISORS LLC | Director | Dec 19, 2022 | Buy | $11.01 | 908,265 | 9,999,998 | 1,038,309 | Dec 21, 2022, 04:52 PM |
| Komjathy Andrew | Chief Commercial Officer | Nov 19, 2021 | Buy | $6.70 | 100 | 670 | 100 | Nov 23, 2021, 04:12 PM |
| George Jean | Director | Jun 30, 2015 | Buy | $12.00 | 258,776 | 3,105,312 | 1,133,943 | Jun 30, 2015, 06:47 PM |
| GALAKATOS NICHOLAS | Director | Jun 30, 2015 | Buy | $12.00 | 376,695 | 4,520,340 | 2,752,488 | Jun 30, 2015, 06:47 PM |
| Clarus Lifesciences II, L.P. | 10% Owner | Jun 30, 2015 | Buy | $12.00 | 376,695 | 4,520,340 | 2,752,488 | Jun 30, 2015, 06:47 PM |
| SVLSF V, LLC | 10% Owner | Jun 30, 2015 | Buy | $12.00 | 391,090 | 4,693,080 | 2,798,528 | Jun 30, 2015, 06:46 PM |
| MedImmune Ventures, Inc. | 10% Owner | Jun 30, 2015 | Buy | $12.00 | 223,439 | 2,681,268 | 1,632,652 | Jun 30, 2015, 06:45 PM |
| Laufer Ron | Director | Jun 30, 2015 | Buy | $12.00 | 223,439 | 2,681,268 | 1,632,652 | Jun 30, 2015, 06:45 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Morabito Christopher | Chief Medical Officer | 04/01/2024 | 38,700 |
| Morabito Christopher | Chief Medical Officer | 04/01/2024 | 135,939 |
| PERCEPTIVE ADVISORS LLC | Director | 02/01/2024 | 29,999,522 |
| Morabito Christopher | Chief Medical Officer | 01/29/2024 | 35,604 |
| Morabito Christopher | Chief Medical Officer | 01/26/2024 | 3,096 |
| Morabito Christopher | Chief Medical Officer | 01/29/2024 | 102,552 |
| Morabito Christopher | Chief Medical Officer | 01/26/2024 | 8,812 |
| PERCEPTIVE ADVISORS LLC | Director | 12/21/2023 | 4,588,000 |
| PERCEPTIVE ADVISORS LLC | Director | 10/16/2023 | 6,999,996 |
| PERCEPTIVE ADVISORS LLC | Director | 12/19/2022 | 9,999,998 |
| Komjathy Andrew | Chief Commercial Officer | 11/19/2021 | 670 |
| George Jean | Director | 06/30/2015 | 3,105,312 |
| GALAKATOS NICHOLAS | Director | 06/30/2015 | 4,520,340 |
| Clarus Lifesciences II, L.P. | 10% Owner | 06/30/2015 | 4,520,340 |
| SVLSF V, LLC | 10% Owner | 06/30/2015 | 4,693,080 |
| MedImmune Ventures, Inc. | 10% Owner | 06/30/2015 | 2,681,268 |
| Laufer Ron | Director | 06/30/2015 | 2,681,268 |
Load More Insider Transactions
FUNDS WITH A POSITION IN ASTRIA THERAPEUTICS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| VIVO CAPITAL, LLC | 2,482,727 | 1.56% | 47.68% | Other |
| BlackRock Inc. | 2,455,653 | 0.00089% | 12.41% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 697,215 | 0.00056% | 39.77% | Other |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 425,364 | 0.04% | -70.75% | Growth |
| UBS OCONNOR LLC | 78,120 | 0.04% | -37% | Value |
| RENAISSANCE TECHNOLOGIES LLC | 14,200 | 0.00017% | 40.59% | Other |
CHANGE IN SHARES OUTSTANDING FOR ASTRIA THERAPEUTICS INC
STOCK BUYBACKS FOR ASTRIA THERAPEUTICS INC
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
7.43%
1Q
06/30/2023
7.50%
2Q
03/31/2023
7.80%
3Q
BUYBACK ANNOUNCEMENT(S) FOR ASTRIA THERAPEUTICS INC
LOADING...